- Ticker
- ACAD
- Price
- 17.80
- Stock movement down
- -0.21 (-1.17%)
- Company name
- ACADIA Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.89B
- Ent value
- 2.96B
- Price/Sales
- 5.58
- Price/Book
- 7.21
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 356.00
- PEG
- -
- EPS growth
- -10.76%
- 1 year return
- -2.63%
- 3 year return
- -4.81%
- 5 year return
- -7.90%
- 10 year return
- -3.38%
Last updated: 2024-04-08
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ACAD does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.58 |
| Price to Book | 7.21 |
| EV to Sales | 5.72 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 162.23M |
| EPS (TTM) | -1.34 |
| FCF per share (TTM) | -0.71 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 517.24M |
| Gross profit (TTM) | 507.07M |
| Operating income (TTM) | -223.60M |
| Net income (TTM) | -215.97M |
| EPS (TTM) | -1.34 |
| EPS (1y forward) | 0.05 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 98.03% |
| Operating margin (TTM) | -43.23% |
| Profit margin (TTM) | -41.76% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 114.85M |
| Net receivables | 63.08M |
| Total current assets | 507.94M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 587.81M |
| Accounts payable | 12.75M |
| Short/Current long term debt | 52.70M |
| Total current liabilities | 125.63M |
| Total liabilities | 187.40M |
| Shareholder's equity | 400.41M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -114.03M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -114.03M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -53.94% |
| Return on Assets | -36.74% |
| Return on Invested Capital | -53.94% |
| Cash Return on Invested Capital | -28.48% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 17.87 |
| Daily high | 18.08 |
| Daily low | 17.63 |
| Daily Volume | 1.73M |
| All-time high | 57.00 |
| 1y analyst estimate | 22.50 |
| Beta | 0.58 |
| EPS (TTM) | -1.34 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 6 May 2024 |
Downside potential
Loading...
Downside potential data
| ACAD | S&P500 | |
| Current price drop from All-time high | -68.77% | -0.85% |
| Highest price drop | -96.29% | -56.47% |
| Date of highest drop | 12 Nov 2010 | 9 Mar 2009 |
| Avg drop from high | -48.54% | -11.35% |
| Avg time to new high | 54 days | 13 days |
| Max time to new high | 1820 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.89B
Marketcap category
Mid-cap
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.
Employees
511
Website
Investor relations
-
SEC filings
CEO
Stephen R. Davis
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page